{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01298830",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CM GLP-1/01"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2007-004516-31",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "CellMed AG, a subsidiary of BTG plc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage",
      "OfficialTitle": "GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2013",
      "OverallStatus": "Terminated",
      "WhyStopped": "Need for improvement of study medication. Safety data collected sufficient. No further gain in knowledge expected.",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2008"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2011",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2011",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 15, 2011",
      "StudyFirstSubmitQCDate": "February 16, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 18, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 25, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 26, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Dr. med. Peter Geigle / CEO",
        "ResponsiblePartyOldOrganization": "CellMed AG"
      },
      "LeadSponsor": {
        "LeadSponsorName": "CellMed AG, a subsidiary of BTG plc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Intracerebral Hemorrhage (ICH)"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Basic Science",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "11",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "GLP-1 CellBeads",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: GLP-1 CellBeads"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "GLP-1 CellBeads",
            "InterventionDescription": "GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "GLP-1 CellBeads"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Neurological conditions",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nConfirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance Tomography (MRT)\nPatients who need by judgement of a clinical neurologist or neurosurgeon surgical removal of the blood clot due to its space-occupying effects\nAge greater or equal 18 years for men\nAge greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or surgical sterilisation at least 3 months before study start)\nFor all other women age greater or equal 50 years with last menstrual bleeding at least one year before study start\nMinimum hematoma diameter of 2 cm as measured in baseline CCT or MRT\nSigned, written informed consent of patient or consent/assertion from the patient's legally acceptable representative/affiliated if the patient is unable to provide informed consent\n\nExclusion Criteria:\n\nParticipation in any other clinical trial within the past 3 months or ongoing\nOccurrence of inconsistency with initial diagnosis at baseline during surgery of the patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or trauma\nPatients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into the brainstem\nPatients with severe pre-existing physical or mental disability or severe comorbidity that interferes with the assessment of outcome\nAllergy to contrast media (MRT)\nAcute infection\nMuscular, neurological, or vascular insufficiency of the respective tissue\nPolypropylene incompatibility\nAcute immunosuppressive medication\nPatient after organ transplantation\nPatient with immune depression\nPatients with a high probability of spontaneous recovery or showing rapidly improving signs\nPatients with extensive intracranial hemorrhages or with deep hemispheric localisation of the clots\nPatients whose diagnosis of ICH is uncertain",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Thomas Brinker, Prof. Dr.med.",
            "OverallOfficialAffiliation": "International Neuroscience Institute Hanover",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Neurochirurgische Klinik und Neurologische Klinik des Universitätsklinikums Heidelberg",
            "LocationCity": "Heidelberg",
            "LocationState": "Baden-Württemberg",
            "LocationZip": "69120",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Neurochirurgische Klinik der Universität Erlangen-Nürnberg",
            "LocationCity": "Erlangen",
            "LocationState": "Bavaria",
            "LocationZip": "91054",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Klinik für Neurochirurgie Klinikum Bogenhausen Akademisches Lehrkrankenhaus der Technischen Universität München",
            "LocationCity": "München",
            "LocationState": "Bavaria",
            "LocationZip": "81925",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Klinikum Region Hannover Krankenhaus Nordstadt, Klinik für Neurologie",
            "LocationCity": "Hannover",
            "LocationState": "Lower Saxony",
            "LocationZip": "30167",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "International Neuroscience Institute",
            "LocationCity": "Hannover",
            "LocationState": "Lower Saxony",
            "LocationZip": "30625",
            "LocationCountry": "Germany"
          },
          {
            "LocationFacility": "Klinik für Neurochirurgie Medizinische Hochschule Hannover",
            "LocationCity": "Hannover",
            "LocationState": "Lower Saxony",
            "LocationZip": "30625",
            "LocationCountry": "Germany"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000002543",
            "ConditionMeshTerm": "Cerebral Hemorrhage"
          },
          {
            "ConditionMeshId": "D000006470",
            "ConditionMeshTerm": "Hemorrhage"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020300",
            "ConditionAncestorTerm": "Intracranial Hemorrhages"
          },
          {
            "ConditionAncestorId": "D000002561",
            "ConditionAncestorTerm": "Cerebrovascular Disorders"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M21459",
            "ConditionBrowseLeafName": "Stroke",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8708",
            "ConditionBrowseLeafName": "Hemorrhage",
            "ConditionBrowseLeafAsFound": "Hemorrhage",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4944",
            "ConditionBrowseLeafName": "Cerebral Hemorrhage",
            "ConditionBrowseLeafAsFound": "Intracerebral Hemorrhage",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21266",
            "ConditionBrowseLeafName": "Intracranial Hemorrhages",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4962",
            "ConditionBrowseLeafName": "Cerebrovascular Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M8195",
            "InterventionBrowseLeafName": "Glucagon",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M26150",
            "InterventionBrowseLeafName": "Glucagon-Like Peptide 1",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Gast",
            "InterventionBrowseBranchName": "Gastrointestinal Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}